Faron Pharmaceuticals Oy (FARN)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014087)
◆英語タイトル:Faron Pharmaceuticals Oy (FARN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014087
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:47
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:フィンランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Faron Pharmaceuticals Oy (Faron Pharma) is a drug company that carries out clinical stage drug discovery and development. The company’s product portfolio includes traumakine; clevegen; farbetic, an AOC3 inhibitor and D-ARDS, a diagnostic tool. Its traumakine clinical programme manages the treatment of acute respiratory distress syndrome (ARDS) an orphan lung disease. Faron’s drug platform traumakine prevents vascular leakage through the injured endothelium of several central organs. Its pipeline products concentrates on the therapeutic areas of acute organ traumas, cancer immunotherapy and vascular damage. The company also works in collaboration with academic institutions. Faron Pharma is headquartered in Turku, Finland.

Faron Pharmaceuticals Oy (FARN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Faron Pharmaceuticals Oy, Medical Devices Deals, 2011 to YTD 2017 10
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Faron Pharma Enters Into Licensing Agreement With Maruishi Pharma For Traumakine 12
Faron Pharma Enters into Agreement with University of Birmingham Medical School 13
Faron Pharma Enters into Agreement with Selexis 14
Faron Pharma Enters into Joint Development Partnership with Turku PET Center 15
Licensing Agreements 16
Pharmbio Korea Enters into Licensing Agreement with Faron Pharma 16
China Medical System Enters into Licensing Agreement with Faron Pharma 17
Equity Offering 18
Faron Pharma Raises USD11.9 Million in Private Placement of Shares 18
Faron Pharma Raises USD1.3 Million in Rights Offering of Shares 19
Faron Pharma to Raise USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 20
Faron Pharma Raises USD0.3 Million in Private Placement of Shares 21
Faron Pharma Raises USD6 Million in Private Placement of Shares 22
Faron Pharma Raises USD10.4 Million in Private Placement of Shares 23
Faron Pharma Raises Funds in IPO 25
Acquisition 26
A&B Acquires 15.72% Stake in Faron Pharma for USD5.6 Million 26
Faron Pharmaceuticals Oy – Key Competitors 27
Faron Pharmaceuticals Oy – Key Employees 28
Faron Pharmaceuticals Oy – Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
Financial Announcements 30
Sep 06, 2017: Faron Pharmaceuticals: Interim Results for the six months ended 30 June 2017 30
Mar 29, 2017: Faron Pharmaceuticals: Final Results for the year ended 31 December 2016 32
Feb 09, 2017: Faron update for 2017 38
Sep 05, 2016: Faron Pharmaceuticals Announces Interim Results for the six months ended 30 June 2016 39
Mar 10, 2016: Faron Pharmaceuticals: Annual Results for the year ended 31 December 2015 40
Corporate Communications 41
Apr 19, 2017: Faron Pharmaceuticals: Proposed Board Changes 41
Product News 42
06/14/2016: Faron Provides Update On Clevegen at R&D Day 42
06/14/2016: Faron Provides Update on Traumakine at R&D Day 43
05/26/2016: Faron Expands R&D Strategy for Novel Immunotherapy Drug Candidate, Clevegen 44
Clinical Trials 45
Oct 24, 2016: First Traumakine Phase III patient in Japan recruited for the treatment of acute respiratory distress syndrome and Update on Pan-European Phase III Traumakine trial 45
Jan 07, 2016: Positive top-line results from the Japanese Phase II study of Traumakine for the treatment of ARDS 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Faron Pharmaceuticals Oy, Deals By Therapy Area, 2011 to YTD 2017 9
Faron Pharmaceuticals Oy, Medical Devices Deals, 2011 to YTD 2017 10
Faron Pharmaceuticals Oy, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Faron Pharma Enters Into Licensing Agreement With Maruishi Pharma For Traumakine 12
Faron Pharma Enters into Agreement with University of Birmingham Medical School 13
Faron Pharma Enters into Agreement with Selexis 14
Faron Pharma Enters into Joint Development Partnership with Turku PET Center 15
Pharmbio Korea Enters into Licensing Agreement with Faron Pharma 16
China Medical System Enters into Licensing Agreement with Faron Pharma 17
Faron Pharma Raises USD11.9 Million in Private Placement of Shares 18
Faron Pharma Raises USD1.3 Million in Rights Offering of Shares 19
Faron Pharma to Raise USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 20
Faron Pharma Raises USD0.3 Million in Private Placement of Shares 21
Faron Pharma Raises USD6 Million in Private Placement of Shares 22
Faron Pharma Raises USD10.4 Million in Private Placement of Shares 23
Faron Pharma Raises Funds in IPO 25
A&B Acquires 15.72% Stake in Faron Pharma for USD5.6 Million 26
Faron Pharmaceuticals Oy, Key Competitors 27
Faron Pharmaceuticals Oy, Key Employees 28

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Faron Pharmaceuticals Oy (FARN)-製薬・医療分野:企業M&A・提携分析(Faron Pharmaceuticals Oy (FARN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆